As of June 2026, according to Laboratory Corp Of America Holdings's latest financial report, the company's current EPS (TTM) is $11.36. In 2025, the company recorded an earnings per share (EPS) of $10.54, which represents an increase compared to its EPS of $8.89 in 2024. Laboratory Corp Of America Holdings's earnings per share for the quarterly report ending on Mar 31, 2026 was $3.37.
The annual EPS in 2025 was $10.54, an increase of 18.6% from $8.89 in 2024. For the quarter ending Mar 31, 2026, the EPS was $3.37, showing a 32.7% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2026 is $11.36. In 2024, the annual EPS was $8.89, showing an increase of 85.2% from 2023.
Laboratory Corp Of America Holdings has recorded an increase in EPS of 32.7% over the last 12 months (YoY, quarterly). Over a three-year span, the company had an average EPS growth of -9.1% per year. Laboratory Corp Of America Holdings had an average annual EPS growth rate of -8% over the last 5 years. When measured over a ten-year period, LH's average EPS growth rate was 9.1%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| QGEN Qiagen NV | 19.96 | 415.8% | 1.8% | 3.9% |
| DGX Quest Diagnostics Inc | 21.52 | 14% | 3.1% | -3.5% |
| LH Laboratory Corp Of America Holdings | 22.81 | 18.6% | -9.1% | -8% |
| IDXX Idexx Laboratories Inc | 39.88 | 22.3% | 17.5% | 14.1% |
| NEO Neogenomics Inc | N/A | -35.5% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.